Prelude Therapeutics (PRLD) Assets Average (2020 - 2026)

Prelude Therapeutics has reported Assets Average for 7 years, with the latest figure at $130.5 million in Q1 2026.

• Quarterly Assets Average fell 17.62% year-over-year to $130.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $130.5 million (down 17.62% YoY) and the FY2025 annual result came in at $158.4 million, down 30.09% from the prior year.
• Assets Average improved to $130.5 million in Q1 2026 per PRLD's latest filing, from $118.0 million in the prior quarter.
• Over five years, Assets Average peaked at $292.9 million in Q1 2022 and troughed at $104.8 million in Q3 2025.
• A 5-year average of $209.8 million and a median of $231.4 million in 2022 frame the typical range for Assets Average.
• The sharpest annual moves came in 2024 and 2025: Assets Average grew 25.3% in 2024, then tumbled 50.26% in 2025.
• Over 5 years, Assets Average stood at $231.4 million in 2022, then rose by 15.85% to $268.1 million in 2023, then tumbled by 30.48% to $186.4 million in 2024, then slumped by 36.67% to $118.0 million in 2025, then grew by 10.54% to $130.5 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $130.5 million, $118.0 million, and $104.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.